Carnitine is a Friend in HFpEF and Foe in HFrEF

Overview

Journal iScience

Publisher Cell Press

Date 2024 Oct 21

PMID 39429785

Authors

Huiqing Wang

Haoran Wei

Mingming Zhao

Junfang Wu

Min Fei

Nan Lin

Rui Zhan

Qingyuan Liu

Qi Zhang

Xiaodong Yao

Yufei Wu

Wenxin Shan

Hongtu Cui

Liang Ji

Bing Pan

Lu Fang

Yujie Zhu

Xin Li

Yansong Guo

Dao Wen Wang

Lemin Zheng

Affiliations

Soon will be listed here.

Abstract

Heart failure (HF) is a global concern, particularly HF with preserved ejection fraction (HFpEF), lacking effective treatments. Understanding the differences of metabolic profiles between HFpEF and HFrEF (heart failure with reduced ejection fraction) patients is crucial for therapeutic advancements. In this study, pseudotargeted metabolomics was employed to analyze for disparities of plasma metabolic profiles between HFpEF and HFrEF in two cohorts: discovery ( = 514) and validation ( = 3368). Plasma-free carnitine levels were significant changed in HF patients. A non-linear and U-shaped (for HFpEF) or J-shaped (for HFrEF) association between circulating free carnitine levels and the composite risk of cardiac events were observed. Interestingly, HFpEF patients with low free carnitine (≤40.18 μmol/L) displayed a poorer survival, contrasting with HFrEF where higher levels (≥35.67 μmol/L) were linked to poorer outcomes, indicating distinct metabolism pathways. In conclusion, these findings offer insights into HFpEF metabolic profiles, suggesting potential therapeutic targets.

References

Ruiz M, Labarthe F, Fortier A, Bouchard B, Legault J, Bolduc V . Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. Am J Physiol Heart Circ Physiol. 2017; 313(4):H768-H781. DOI: 10.1152/ajpheart.00820.2016. View

Hage C, Lofgren L, Michopoulos F, Nilsson R, Davidsson P, Kumar C . Metabolomic Profile in HFpEF vs HFrEF Patients. J Card Fail. 2020; 26(12):1050-1059. DOI: 10.1016/j.cardfail.2020.07.010. View

Vescovo G, Ravara B, Gobbo V, Libera L . Inflammation and perturbation of the l-carnitine system in heart failure. Eur J Heart Fail. 2005; 7(6):997-1002. DOI: 10.1016/j.ejheart.2004.11.010. View

Liu J, Zhao M, Zhou J, Liu C, Zheng L, Yin Y . Simultaneous targeted analysis of trimethylamine-N-oxide, choline, betaine, and carnitine by high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1035:42-48. DOI: 10.1016/j.jchromb.2016.09.026. View

Hahn V, Knutsdottir H, Luo X, Bedi K, Margulies K, Haldar S . Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. Circulation. 2020; 143(2):120-134. PMC: 7856095. DOI: 10.1161/CIRCULATIONAHA.120.050498. View

Ho F, Gray S, Welsh P, Petermann-Rocha F, Foster H, Waddell H . Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. BMJ. 2020; 368:m688. PMC: 7190059. DOI: 10.1136/bmj.m688. View

Peng L, Song Z, Zhao C, Abuduwufuer K, Wang Y, Wen Z . Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics. Phenomics. 2023; 3(1):34-49. PMC: 9883375. DOI: 10.1007/s43657-022-00069-8. View

Naito J, Ohashi H, Ohno M, Sugiyama M, Hayakawa K, Kunishima A . Long-Term Levocarnitine Ameliorates Left Ventricular Diastolic as Well as Systolic Dysfunction in Hemodialysis Patients　- Multi-Center Study. Circ Rep. 2021; 1(11):508-516. PMC: 7897577. DOI: 10.1253/circrep.CR-19-0075. View

Wu L, Shi Y, Kong C, Zhang J, Chen S . Dietary Inflammatory Index and Its Association with the Prevalence of Coronary Heart Disease among 45,306 US Adults. Nutrients. 2022; 14(21). PMC: 9656485. DOI: 10.3390/nu14214553. View

10.

Dunlay S, Roger V, Redfield M . Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14(10):591-602. DOI: 10.1038/nrcardio.2017.65. View

11.

Govindarajulu U, Malloy E, Ganguli B, Spiegelman D, Eisen E . The comparison of alternative smoothing methods for fitting non-linear exposure-response relationships with Cox models in a simulation study. Int J Biostat. 2010; 5(1):Article 2. PMC: 2827890. DOI: 10.2202/1557-4679.1104. View

12.

Zheng F, Zhao X, Zeng Z, Wang L, Lv W, Wang Q . Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry. Nat Protoc. 2020; 15(8):2519-2537. DOI: 10.1038/s41596-020-0341-5. View

13.

Mirrafiei A, Jayedi A, Shab-Bidar S . The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials. Clin Ther. 2024; 46(5):404-410. DOI: 10.1016/j.clinthera.2024.03.002. View

14.

Zhao M, Wei H, Li C, Zhan R, Liu C, Gao J . Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat Commun. 2022; 13(1):1757. PMC: 8976029. DOI: 10.1038/s41467-022-29060-7. View

15.

Zhao H, Shui B, Zhao Q, Hu Z, Shu Q, Su M . Quantitative Metabolomics Reveals Heart Failure With Midrange Ejection Fraction as a Distinct Phenotype of Heart Failure. Can J Cardiol. 2020; 37(2):300-309. DOI: 10.1016/j.cjca.2020.03.024. View

16.

Koeth R, Wang Z, Levison B, Buffa J, Org E, Sheehy B . Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19(5):576-85. PMC: 3650111. DOI: 10.1038/nm.3145. View

17.

Huang J, Li C, Song Y, Fan X, You L, Tan L . ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure. Cell Discov. 2018; 4:57. PMC: 6198009. DOI: 10.1038/s41421-018-0058-6. View

18.

Wei H, Zhao M, Huang M, Li C, Gao J, Yu T . FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population. Front Med. 2021; 16(2):295-305. DOI: 10.1007/s11684-021-0857-2. View

19.

Zhao J, Burgess S, Fan B, Schooling C . L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. BMC Med. 2022; 20(1):272. PMC: 9434903. DOI: 10.1186/s12916-022-02477-z. View

20.

Rizk A, Mayhoub G, Aleem S, Mokhtar M . Plasma carnitine levels as a marker of impaired left ventricular functions. Mol Cell Biochem. 2000; 213(1-2):37-41. DOI: 10.1023/a:1007142919941. View